United States · 
What does Avego Management invest in?
Avego Management invests most often at Growth and Series E (100% of the rounds on record), in sectors such as Sdg, Social and Underserved.
Avego Management highlights
- 01
2 cheques in the last 12 months
- 02
Mostly Growth and Series E: 100% of its rounds
- 03
Led 2 rounds
What they do
We are investing our own capital.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- SdgSocialUnderserved
- Based in
- Alpharetta, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first3 appearances
- 2026
1 round
- Oct
- 2025
2 rounds
- Nov
- Jan
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration4 named
AAAlyssa Arden RomanoChief Compliance Officer and Chief Financial OfficeriForm ADV
BVBalaji VenkataramanPartner, Managing MemberiForm ADV
JMJames Moncure FlexnerPartner, MemberiForm ADV
TRThomas Richard VandervortPartner, MemberiForm ADV
We also hold 3 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$918Massets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Avego Management, LLC
- SEC number
- CRD 310520
Funds on its Form ADV
6 private funds, $861M in gross assets · filed Oct 2024
Private equity 3Hedge 2Venture 1
- Avego Healthcare Capital Fund II, L.P.Private equity33 investors$286M
- Avego Healthcare Capital, L.P.Private equity5 investors$273M
- Velan Capital Master Fund L.P.Hedge13 investors$178M
- Avego Bioscience Capital, L.P.Venture19 investors$92M
- Velan Capital SPV I LLCHedge37 investors$18M
- AHC-II AGR Partners, L.P.Private equity5 investors$14M
What they claim to have backed
From their own portfolio page (on their website)
11 of 17 we have independently watched raise
AlentisAltoCellcentricEpibiologicsEvommuneHealthoutlookImmunocoreJaspertherapeuticsMytomorrowsTrexXcellbioAtomvieCariboubioInvestor PortalPbsbiotechSebelapharmaSentynl
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.